Treatment of Inflammatory Bowel Disease with Biologics
10 Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to the ...
11 Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/2 ...
© Springer International Publishing AG 2018 13 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease wi ...
14 Currently, biologic therapies including anti-TNFα agents, utilized with or without concomitant immunomodulators, are consider ...
15 in recent years. While resolution of patient symptoms was historically utilized as a primary goal of therapy, recent studies ...
16 Table 2.1 Summary of efficacy for induction and maintenance clinical trials of anti-TNF α medications in UC Anti-TNF α^ medic ...
17 (continued) Adalimumab Reinisch et al. [ 18 ] Induction (ULTRA-1) 576 patients with moderate-to-severe UC despite corticoster ...
18 Table 2.1 (continued) Golimumab Sandborn et al. [ 28 ] Induction with SC golimumab (PURSUIT-SC) 761 patients Randomized to pl ...
19 weight or placebo administered at weeks 0, 2, and 6 and then every 8 weeks through week 22 in ACT 2 and week 46 in ACT 1 [ ...
20 484 infliximab- treated patients in ACT 1 and ACT 2, 229 patients continued to receive infliximab in the extension studies. O ...
21 The ULTRA 1 study protocol originally included one adalimumab group of patients receiving adalimumab 160 mg at week 0, 80 mg ...
22 response, and mucosal improvement rates at week 52 for prior week 8 responders were 20%, 45%, and 45%, respectively, compared ...
23 Ulcerative Colitis Research Studies Utilizing an Investigational Treatment- Subcutaneous (PURSUIT-SC) study evaluated the saf ...
24 Long-Term Safety and Efficacy Data Authors published long-term safety and efficacy data on SC golimumab in 2016 [ 30 ]. 1240 ...
25 infections, 2% developed neoplasms, and 2% died [ 33 ]. Although results suggest higher risk in older populations, the retros ...
26 any infections or comorbid illness that would preclude use of anti-TNFα therapy. Additionally, guidelines recommend appropria ...
27 infrequency of every 2 months of intravenous dosing. Furthermore ease of intrave- nous access is important to consider as pat ...
28 remission rates varied widely in retrospective studies, and currently only one placebo- controlled trial has evaluated the ef ...
29 with their providers to consider the role of vaccines to reduce the risk of preventable illnesses [ 45 , 46 ]. Patients shoul ...
30 trying a second anti-TNFα agent. We do not advocate switching unless the patient has lost response or been intolerant to a sp ...
«
1
2
3
4
5
6
7
8
9
10
»
Free download pdf